Arena's lorcaserin a year out from next FDA review
This article was originally published in Scrip
Executive Summary
Arena Pharmaceuticals and commercialization partner Eisai said it could be a year before they resubmit their marketing application to the US FDA for their embattled weight-loss drug lorcaserin, citing the need to complete additional animal studies and a small 10-patient volunteer trial after regulators rejected the drug on concerns that rat data showed an increase in tumours.